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The purpose of this study is to review the literature on the risk of malignancy in patients with inflammatory eye
disease (IED) treated with systemic immunosuppressive (IS) therapy. Relevant databases in transplant medicine,
autoimmune diseases and literature regarding uveitis and scleritis were reviewed. Literature with regards systemic IS
therapy in transplant recipients and patients with autoimmune diseases revealed a significant increase in
malignancies, especially non-melanocytic skin cancers and lymphomas. Studies of patients with IED were limited in
number and scope, with no studies adequately evaluating the incidence of malignancy in these patients. Difficulties
associated with the evaluation of the risk of malignancy associated with IS therapy in patients with IED include the
heterogeneity of the disease and treatment regimens as well as the low frequency of IED, its variable severity and
the lack of adequate long-term follow-up studies. Systemic IS therapy is an important therapeutic option in the
treatment of patients with severe IED. A well-designed, comprehensive, multi-centre long-term follow-up study is
required to evaluate the risk of malignancy in patients with specific IED diseases treated with defined systemic IS
therapy. Until such evidence is available, we recommend the adoption of preventative strategies to help minimise
the risk of malignancy in such patients.
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Introduction
The aims of therapy in patients with inflammatory eye
disease (IED) are to control ocular inflammation, limit
the progression of disease, preserve vision, maintain the
quality of life and prevent local and systemic side effects.
The treatment of severe IED with immunosuppressive
(IS) therapy is a dilemma for the physician in determin-
ing whether the benefits of such therapy outweigh the
risk of inducing other diseases, such as infection and
malignancy. Literature regarding the use of IS therapy in
the treatment of patients with autoimmune diseases in-
dicates that these drugs induce secondary or de novo
malignancies [1-3]. A crucial clinical question is if the
manipulation of the immune system in patients with* Correspondence: d.wakefield@unsw.edu.au
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in any medium, provided the original work is pautoimmune diseases and transplant patients results in
an increase in skin and other malignancies, does this
mean that patients with IED treated with similar long-
term IS therapy are also at such risk? Studies examining
the risk of malignancies in transplant recipients, patients
with human immunodeficiency virus (HIV) and auto-
immune diseases show that suppressing the immune
system predisposes the patients to carcinogenesis [4,5].
The importance of tumour immunosurveillance in
humans has been inferred from clinical observations. The
majority of evidence concerning the effects of IS therapy
on the host immune response and tumour development is
derived from studies of transplant recipients. The effect-
iveness of IS therapy in improving the outcome of organ
transplantation has resulted in the development of malig-
nancies and cardiovascular disease emerging as the major
causes of patient mortality, rather than graft rejection as
previously observed [1,3,6]. Solid organ transplant reci-
pients given systemic immunosuppressive therapy require
lifelong therapy. In contrast, patients with systemicOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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ber of immunosuppressive drugs, often concurrently and
over a shorter time course, but nonetheless may still be
predisposed to increased tumour risk [7].
Patients with severe IED are often treated with sys-
temic immunosuppressive therapy. These patients either
do not respond to topical or local therapies, have a type
of IED not controlled by systemic corticosteroids or re-
quire aggressive therapy to prevent progressive vision
loss [8]. The treatment of patients with chronic IED typ-
ically encompasses the use of corticosteroids with add-
itional agents. This is primarily due to the significant
side effects associated with long-term steroid therapy,
and hence agents such as methotrexate (MTX), azathio-
prine (AZA), cyclosporine (CSA), mycophenolate mofetil
(MMF) and, occasionally, alkylating agents (cyclophos-
phamide and chlorambucil) are given concurrently as
steroid-sparing medications. Similarly, the efficacy of IS
therapy in the treatment of a number of diseases such as
ocular cicatricial pemphigoid [9], Behçet's disease [10] and
Wegener granulomatosis [11] has been well documented.
Patients with idiopathic IED do not have an under-
lying systemic disease. Thus, these patients are a suit-
able group to examine the effect of immunosuppression
and malignancy development in otherwise healthy
individuals.
This review examines the evidence regarding the risk
of malignancies in patients treated with systemic im-
munosuppressive therapy. The focus of the review is the
evaluation of the evidence in the settings of transplant
recipient, patients with autoimmune disease and IED.
The aims are to evaluate the available literature and
provide recommendations for further studies and pre-
vention strategies to address this important clinical
question.Materials and methods
A search of articles using the MEDLINE database and
PubMed (National Library of Medicine) was performed
to identify all relevant articles published in the area.
Terms and phrases used for the search included
immunosuppression, malignancy, transplantation, rheu-
matoid disease, autoimmune, uveitis, scleritis and ocular
cicatricial pemphigoid. Articles were included if they
were in English language and if full copies of the articles
could be obtained. Articles were only included if they
were from peer-reviewed journals. Articles were exam-
ined in reference to levels of evidence and recommenda-
tions set by the National Health and Medical Research
Council. Articles were stratified on evidence strength
dependent on study design, which included systematic
reviews, randomised controlled trials (RCTs) and cohort
study data. Review articles and editorials were alsoanalysed and included if evidence was suitable for
inclusion.
Results
The incidence of malignancy in patients treated with IS
therapy differed depending on the specific IS agents and
the indication for therapy. Table 1 illustrates the incidence
of malignancy in solid transplant recipients treated with a
number of immunosuppressive agents. Table 2 highlights
the literature relevant to systemic autoimmune diseases,
and Table 3 summarises the literature regarding systemic
immunosuppressive therapy in patients with IED.
Transplant recipients
Evidence from observational studies of transplant recip-
ients provides significant evidence for the increased risk
of malignancy associated with IS therapy. The emer-
gence of effective systemic IS therapy for allograft
recipients has seen a reduction in immunologic and
non-immunologic graft rejection. However, the major
contributor to mortality following solid organ trans-
plantation is not graft rejection but malignancies and
cardiovascular disease associated with IS therapy [1,34].
The Cincinnati Transplant Tumour Registry pro-
vided a great deal of evidence with regards to the
effects of systemic IS therapy during the era (1980s
and 1990s) when AZA and CSP were the major drugs
used in post-transplantation patients. During 1988, it
reported on 3,351 de novo malignancies in 3,320 pa-
tients treated with systemic IS therapy. Of this group,
3,139 were treated with AZA, and the majority of
malignancies observed were skin (n = 1,255) (40%).
Results of patients treated with CSP highlighted that
the greatest proportion of the 412 tumours were
lymphomas (n = 119) and skin cancers (n = 90) (29%
and 22%, respectively) [34,35].
Skin malignancies, especially non-melanocytic skin
cancer (NMSC), are the most common post-transplant
tumours. Heart and renal transplant recipients are at an
increased risk of squamous cell carcinoma (SCC) and
basal cell carcinoma (BCC) with some studies quantify-
ing the risk as 250 and 65 times higher than the general
population, respectively [2,36]. Two theories have been
proposed to explain this association including (1) solar-
induced mutations coupled with immunosuppression re-
duces tumour surveillance [37] and (2) metabolites from
certain IS agents such as AZA appear phototoxic and
thus increase the skin's sensitivity to ultraviolet light
damage [38]. Previous studies indicate that although
solar radiation may be a major contributor of skin car-
cinogenesis, one increasingly important risk factor is the
host's immune status [6,39,40]. To further illustrate this
observation, one particular study analysed the distribu-
tion of NMSC in sites not exposed to solar radiation and
Table 1 Studies which demonstrated an increased incidence of malignancy associated with systemic
immunosuppressive therapy in transplant recipients
Immunosuppressive
therapy
Study Risk of malignancy References
Azathioprine 1 162 patients with renal allografts treated with AZA (100 to 150 mg/day) found 22 NMSC developed at
3-year follow-up
[12]
2 A comparison of AZA-based therapy (n = 3,139) and CSA-based therapy (n = 412) in transplant
recipients found 1,255 skin malignancies developed in the AZA group (40%) compared to 90 in the
CSA-based group (22%)
[13]
3 12 malignancies, most commonly NMSC, developed in a group of transplant recipients of n = 287
during 12-month follow-up
[14]
4 19 NMSC developed in 7 out of 51 kidney recipients (14%) treated with AZA + prednisone for between
4 and 45 months of treatment; dosing of AZA was kept at approximately 3 mg/kg/day for the duration
after transplantation; 16 SCC, 1 BCC and 3 keratoacanthomas; conclusions suggested that tumours were




1 503 patients with renal allografts were randomised into 3 groups, 2 with varied MMF dosages (2 g,
n = 173; 3 g, n = 164) and a group with AZA therapy (n = 166); 12 malignancies (lymphoma/LPD and
non-skin carcinoma) were found in the group treated with 3 g MMF compared to 8 treated with 2 g
MMF at 3-year follow-up
[12]
Cyclosporine 1 142 malignancies developed in 141 organ transplant recipients treated with cyclosporine, 41%
lymphomas compared to 12% observed in the AZA, prednisone or prednisolone group at 20-year
follow-up
[16]
2 84 malignancies observed in 1,113 patients treated with combination CSA therapy (group 1) found a
1.99% cumulative risk of cancer 2 years post-transplant versus only 0.31% in the control (patients
without CSA exposure or group 2); 43% of tumours observed (n = 38) were NMSC in group 1
compared to 27% in group not exposed to CSA, despite shorter time of exposure
[17]
3 295 renal allograft recipients treated with AZA + prednisone (115) or AZA + prednisone + CSA (180)
found 51 patients (19%) had at least 1 NMSC; it was found that the incidence of NMSC in AZA +
prednisone was 29 per 1,000 person-years compared to 48 per 1,000 years in the group with additional
CSA therapy
[18-21]
Follow-up of 3,823 patients treated with AZA, CYP or chlorambucil for >3 months found a 60-fold increase in NHL and 25-fold increase in SCC during the 5-year
follow-up compared to the general UK and Australia population. SCC and BCC incidence in solid transplant recipients given systemic immunosuppressive therapy
was demonstrated to be a four- to sevenfold increase in low sunshine exposure areas and a 20-fold increase in areas of high sun exposure compared to the
general population. NHL incidence in transplant patients treated with immunosuppressive drugs show a 28- to 49-fold increase compared to
age-matched controls.
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disproportionate between the transplant group on sys-
temic IS and the general population, regardless of
whether sun-exposed or not (100- and 50-fold increase,
respectively) [41].Autoimmune diseases
Studies examining IS therapy in patients with RA are
more directly comparable to studies of patients with IED.
Patients with rheumatic diseases are commonly treated
with similar immune-modulating agents as are patients
with IED, including MTX, MMF, CSP and AZA [7,28].
This literature search revealed that a trend away from
the use of alkylating agents (cyclophosphamide and
chlorambucil) to anti-metabolites and T-cell inhibitors
was initiated by findings of the effectiveness of these
therapies and concerns regarding the risk of carcinogen-
esis resulting from an alkylating agent in the treatment
of autoimmune diseases [22,42]. Kinlen found that 643
patients with RA treated with AZA and cyclophospha-
mide had a 13-fold increase of non-Hodgkin lymphoma
(NHL) compared to the general population [25].A number of studies suggested that RA itself increases
the risk of malignancy regardless of therapy [43,44]. A
large study of 46,000 patients illustrated a 2.7-fold in-
creased risk of malignancy in patients with RA without IS
therapy [45]. This study found a twofold higher incidence
of leukaemia, lymphoma, NHL and myeloma in patients
with RA compared to the Finnish cancer registry. How-
ever, patients with RA on IS therapy demonstrated a
significantly greater increase (often documented up to 10-
to 15-fold increase) in malignancy than in the study by
Isomaki and associates [45]. Baltus and associates, for ex-
ample, found a fourfold increase in malignancies com-
pared to age-matched controls with RA, not on alkylating
agent therapy [22].
A cohort study examining the risk of malignancies in
patients with RA treated with MTX indicate that these
patients are more susceptible to NHL, melanoma and
lung cancer. This long-term follow-up (mean duration
9.3 years) demonstrated a fivefold higher risk of NHL
and a threefold increase in melanoma [27]. Similarly,
case reports examining the effect of MTX on patients
with RA have concluded with similar findings, with
some tumours regressing when therapy was withdrawn
Table 2 Studies which demonstrated an increased incidence of malignancy associated with systemic
immunosuppressive therapy in autoimmune diseases
Immunosuppressive
therapy
Study Risk of malignancy References
Cyclophosphamide 1 461 patients with RA treated with CYP found 5 bladder cancers developed during 5-year follow-up
compared to the expected incidence for the general UK population (0.38)
[22]
2 15 malignancies developed in 81 RA patients treated with CYP with a fourfold increase in the expected
risk of malignancy compared to matched control RA patients not on cytotoxic therapy
[23]
3 119 patients with RA treated with CYP were compared to 119 matched controls that found 37
malignancies in 29 patients and 16 malignancies in 16 patients in the control (p < 0.05); the major
differences were in the number of bladder and NMSC observed (6 and 8, respectively) in the
CYP-treated group and none in the control
[24]
Azathioprine 1 Analysis of data from 643 patients with RA found a 13-fold increase in NHL (whether treated with AZA
or CYP)
[25,26]
2 202 patients with RA treated with AZA compared to 202 RA patients without found a tenfold increase
in NHL in patients treated with AZA and a fivefold increase in RA patients without therapy compared
to the general population approximately 12-year follow-up
Methotrexate 1 458 RA patients treated with MTX found a fivefold increase in NHL and threefold increase in melanoma
compared to the general population with age standardisation; however, risk was increased with prior
CYP exposure prior to MTX (2.5-fold increase)
[27]
Cyclosporine 1 In 1,252 patients with psoriasis followed up for 5 years, it was found that 47 patients (3.8%) developed
malignancies; the standardised incidence ratio was 2.1 as compared with the general population; the
study found a sixfold higher incidence in skin malignancies
[28]
Biologics 1 A RCT of 619 patients with RA treated with adalimumab and with previous MTX exposure found 4
adalimumab-treated patients developed NMSC, 1 non-Hodgkin's lymphoma and 1 adenocarcinoma
[29]
2 In a JIA cohort of 7,812 treated with TNF inhibitors, an increased risk of malignancy in JIA patients
compared to children without JIA was found; however, any increased risk of malignancy in patients
treated with TNF inhibitors was not found
[30]
An epidemiologic study of non-transplant patients treated with systemic immunosuppression treated for greater than 3 months with
AZA, CYP or chlorambucil found an increase in NHL by 11-fold, SCC by fivefold and carcinoma of the bladder by fourfold compared to
the general population
[25]
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associates in patients with psoriasis treated with cyclo-
sporine, in whom found was a sixfold higher incidence
of skin malignancies, mainly SCC, as compared to the
general population [28]. It highlighted that patients
treated for greater than 2 years with agents such as
MTX, retinoids or another immunosuppressive drug had
significantly greater risk than those treated with CSP
alone (RR = 1.8, 2.9, 2.0, respectively).
Since the introduction of biologics, such as TNF-alpha
inhibitors, there has been considerable debate with regard
the risk of malignancy associated with these systemic ISTable 3 Studies which demonstrated an increased incidence o
in IED
Risk of malignancy
8 malignancies were observed in 69 patients with ocular pemphigoid treated
2 SCC, 2 leukemias and 1 breast carcinoma)
537 patients treated with systemic corticosteroids and/or immunosuppressiv
treated with immunosuppressive (n = 330) and the control (n = 207), p > 0.9
46 patients treated with systemic immunosuppressive agents for uveitis were
follow-up and compared to patients who only received corticosteroid therap
comparison to 2 in the control (p < 0.05)agents. The majority of reliable data is derived from
studies of patients with RA participating in RCTs and
meta-analyses of such studies [4,29,47,48]. A meta-
analysis examining adverse effects from infliximab and
adalimumab studies found that malignancies were
significantly more common in patients when given
higher doses of TNF-inhibitors compared to those
given low doses [48]. A recent retrospective cohort
study by Beukelman and associates investigated 7,812
children with juvenile inflammatory arthritis (JIA) and
found that children with this disease had a higher inci-
dence of malignancy, with a standardised incidence ratiof malignancy with systemic immunosuppressive therapy
References
with cyclophosphamide and prednisone therapy (2 BCC, [31]
e therapy found no significant difference between groups
0
[32]
examined for malignancy incidence during a 5-year
y; 8 malignancies occurred in the experimental group in
[33]
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children treated with TNF inhibitors were not at a signifi-
cantly increased risk of malignancy (SIR = 0) [30].
Inflammatory eye disease
There is limited data regarding the long-term sequelae of
systemic IS therapy in the setting of IED. Murray and as-
sociates demonstrated that there was an increased risk of
malignancy in patients treated with systemic IS (n = 46)
therapy in comparison to corticosteroid therapy alone
(n = 31). In this study, patients treated with corticoste-
roids were used as a control group as there is no known
increased risk of malignancy associated with this drug
[33]. The results demonstrated that eight malignancies
occurred in the IS group of patients in comparison to
two in the corticosteroid treated group (p < 0.05). Of
particular note, the study established that the type of
malignancies observed, namely, NHL, skin and cervical
cancers, were similar to neoplasms that developed in
patients treated with systemic IS therapy for allografts
recipients and other autoimmune diseases. Lane et al.
in, a larger study (n = 537), concluded that there was
not a significantly increased risk of malignancy in pa-
tients with IED treated with IS therapy compared to pa-
tients treated with corticosteroid alone (p > 0.90) [32].
A large retrospective cohort study which examined
cancer mortality risk in patients with IED treated with
IS therapy found no increased risk of malignancy.
Kempen and associates examined the overall mortality
of patients with IED treated with systemic IS therapy.
This study examined patients treated at five tertiary
ocular inflammatory centres between 1979 and 2005
(n = 7957) and evaluated the overall mortality by
identifiers on US National Death Index [49]. The con-
clusion drawn from this study indicated that patients
with IED who were treated with systemic IS were not
at an increased risk of death from malignancy. How-
ever, the study did suggest that TNF inhibitors dou-
bled a patient's risk of malignancy. Crucially, the study
did not address the prevalence of non-fatal malignan-
cies in this cohort.
Discussion
There is irrefutable evidence derived from studies of
transplant recipients and patients with autoimmune dis-
eases that IS therapy is associated with increased malig-
nancy risk. The limited evidence of malignancy associated
with systemic immunosuppressive therapy in patients with
IED highlights that this clinical issue has not yet been
appropriately addressed.
Data derived from transplant registries have strongly
established the potential risk of malignancy that results
from prolonged IS therapy in order to preserve graft
function [39,50,51]. The ability to ascertain whethercertain IS drugs are associated with a higher malignancy
potential is also influenced by previous patient exposure
to other IS therapies. These drugs are typically used in
combination or consecutively as the introduction of
newer IS agents, such as calcineurin inhibitors and bio-
logics, became more widely used [34]. Long-term follow-
up studies of transplant recipients revealed that neoplasms
appeared on average 5 years after transplantation and the
commencement of IS therapy [1,41]. Immunosuppressive
therapy for allograft recipients differs significantly in
regards to dosing and cumulative exposure when com-
pared to patients treated for systemic inflammatory dis-
eases. Similarly, the systemic inflammatory state induced
by the allograft may drive carcinogenesis, exacerbated by
the use of IS therapy [3]. Therefore, it would be naive to
affirm the same risk of developing neoplasia without con-
sidering that there may be marked differences in risk
between different groups of patients.
The literature on the risk carcinogenesis in patients
with RA and other inflammatory diseases treated with IS
drugs is divided. Numerous studies indicate an increased
risk of malignancy with IS therapy, whilst other studies
suggest that the increased risk is due to the disease itself
(e.g. rheumatoid arthritis [7], psoriasis [28] and Sjögren's
disease [52]). Isomaki et al. suggested that the baseline
risk of malignancy in patients with RA might be due to
chronic activation of the immune system, leading to an
increased incidence of lymphoproliferative disorders.
The majority of studies indicate that patients with either
rheumatoid arthritis or psoriasis are at an increased risk
of neoplasia; however, patients treated with systemic IS
therapy have a significantly greater incidence of tumours
[53-55]. A number of authors have factored in the base-
line risk of neoplasia in patients and compared patients
on IS therapy for RA and patients not on such therapy
[56]. Other studies did not account for this baseline risk
of malignancy in RA, which may inflate their malignancy
incidence findings [57].
A well-designed study which accurately addresses the
concern that systemic IS therapy in IED may predispose
to malignancy has not been conducted, and there is lim-
ited literature specific to the long-term use of IS therapy
in patients with IED. Studies that have examined this
important issue have a number of significant shortcom-
ings. The study conducted by Murray et al. established
that there was an increased risk of malignancy; however,
the findings are affected by a number of important fac-
tors. These include a small sample size (n = 87) and fail-
ure to account for pre-exposure risk of malignancy and
not addressing IED with systemic disease associations in
the analysis of the results [33]. The limited patient sam-
ple size resulted in insufficient statistical power for valid
conclusions to be drawn. Lane and associates did not
find an increased risk of malignancy in patients treated
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affected by the relatively short-term follow-up period
(mean 1.34 years). It is evident that long-term follow up
(often >5 years) is necessary in studies of patients ex-
posed to IS therapy in order to provide a more accurate
clinical picture [1,58]. Kempen et al. suggested that sys-
temic IS therapy does not increase the risk of cancer
mortality in patients with IED [49]. The study, however,
did not address the incidence of non-fatal neoplasia in
patients treated with systemic IS therapy for IED. The
type of malignancy, grade or histopathology for tumours
was not obtained because the primary outcome of this
study was defined as the cause of death on certificates
identified on the US Death Index. Studies suggest that pa-
tients who develop malignancies associated with systemic
IS therapy have tumours such as NMSC or lymphomas,
which are treatable and may not directly increase mortal-
ity; however, they may have a significant impact on mor-
bidity and the patient's quality of life [7,48,54]. Another
important issue for ophthalmologists is the need for a
regular, focussed and complete physical examination to
ensure that the sites of common immunosuppression-
related malignancies, such as skin, lymph nodes and
cervix, are examined. This by necessity requires a careful
systemic review and the assistance of other physicians,
which may not be readily available in busy eye clinics.
More recently developed therapeutic agents, which are
increasingly utilised in the treatment of ocular inflam-
mation, target the activity of inflammatory cells and
cytokine signalling. Limited long-term data exists on
whether the use of these agents alters the body's ability
to detect defective or pre-cancerous cells [59]. Data with
regards the safety of biologics (e.g. TNF-α inhibitors) in
the treatment of patients with IED are limited due to the
recent use of these agents in this setting and a lack of
long-term follow-up studies. A number of studies have
highlighted the possibility of increased risk of malig-
nancy although none of these studies involved a large
patient sample with an appropriate long-term follow-up
[60,61]. Similarly, issues related to pre-exposure to MTX
and other systemic IS therapy may act as confounders
on data reliability.
Recommendations for future studies
In order to properly address the question of whether the
risk of malignancy increases in patients with IED treated
with systemic IS therapy, a large collaborative multi-
centre prospective cohort study with a long-term follow-
up and regular careful systemic evaluation is required.
The study design needs to incorporate methodology that
addresses possible synergistic factors in carcinogenesis.
Examples of such factors include past history and family
history of malignancy, smoking status and occupation.
In particular reference to NMSC, data on lifetime sunexposure and complexion should be obtained as in the
study of Glover et al. [62]. This would evaluate whether
an increase in malignancy in IED patients on systemic IS
therapy is due predominantly to the immunosuppression
or requires the addition of other factors and thus an in-
direct causation. Furthermore, comparison of patients
with similar IED diseases treated with corticosteroid
monotherapy as controls, compared to those treated
with systemic IS therapy, would address issues with re-
gard to the baseline malignancy risk in patients with
IED. It could be argued that patients who are treated
with systemic IS therapy may have more severe disease
and thus are at significantly greater risk of carcinogen-
esis. Whilst this is true in the setting of autoimmune dis-
ease and transplant recipients, this same conclusion has
not been demonstrated in patients with idiopathic IED.
An investigation of the malignancy risk associated
with specific IED entities would provide crucial infor-
mation. A number of tertiary IED centres would be re-
quired to achieve this aim by examination of a
sufficiently large number of patients. Another important
aspect of establishing the carcinogenesis potential of
systemic IS therapy in patients with IED is to evaluate
any dose–response relationship, which has not been
conducted in patients with IED. This will ascertain
whether higher dose IS therapy correlates with an in-
creased risk of malignancy in patients with IED.
The large variety of systemic diseases associated with
IED (e.g. Behçet's disease, sarcoidosis, Vogt-Kayangi
-Harada disease, etc.) poses a problem in an investiga-
tion into malignancy risk. Patients with an associated
systemic disease may have a significantly increased risk
of malignancy compared to those with IED without an
underlying disease. A large study, examining the com-
mon diseases associated with uveitis (with sufficient stat-
istical power), is necessary to address this issue. Previous
studies have tried to identify whether Behçet's disease is
associated with an increased risk of malignant disease,
but the available literature, consisting mainly of case re-
ports, suggests no significant association [63,64]. An in-
vestigation into the baseline risk of neoplasia in patients
with sarcoidosis also does not support such a correlation
[65]. The baseline risk of malignancy has not been
established for patients with IED, with or without sys-
temic manifestations.
Prevention
A crucial aspect of the issue of the relationship between
systemic IS therapy and cancer risk is how this can be
minimised or prevented. Until it is proven beyond reason-
able doubt that patients with IED treated with IS therapy
are not at an increased risk of malignancy, it would seem
prudent to adopt strategies to minimise such risk. Our sug-
gestions for such an approach are outlined in Table 4.
Table 4 Strategy to reduce risk of systemic immunosuppressive therapy related malignancies
Strategy
Pre-treatment Careful pre-treatment evaluation of patients for presence of immunodeficiency (e.g. HIV), past or family history of malignancy and
pre-malignant conditions (e.g. Bowen's disease, CIN of cervix, GIT polyps, leukoplakia of lip)
Dosages and
therapy
Minimise dose and duration of immunosuppressive therapy (e.g. use of alkylating agents, such as cyclophosphamide for <12
months) - consider drugs with less oncogenic potential (e.g. MTX, mTOR inhibitors (sirolimus))
Education Patient education - stop smoking, avoid excessive exposure to UV radiation, immunisation against HPV, regular self-examination
(e.g. skin, lips, breast)
Follow-up Regular and annual review - screening for common immunosuppressive therapy associated malignancies (e.g. skin, cervix,
bladder, lymph nodes)
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Kidney Disease: Improving Global Health Outcomes
group. In relation to skin and lip cancers, it is
recommended that patients should be educated about
the risk of skin cancer, especially in subjects with a
history of high levels of sun exposure and who are
fair-skinned and/or have a history of previous NMSC
[37]. All patients should be encouraged to practice
regular self-examination and have annual skin and lip
examinations by health professionals. Recommenda-
tions for non-skin cancer-related malignancies are the
same as for cancer screening of the general population,
with emphasis on cervical, breast, colon, renal and
haematological examinations [66]. Immunisation against
the human papilloma virus may also help reduce the
incidence of cervical cancer in this population. Epi-
demiological studies of renal transplant patients indicate
that the duration and intensity of IS therapy influence
the incidence of post-transplant malignancies. Thus,
modulation of IS therapy and minimising exposure to
drugs known to have a high association with malignancy,
such as cyclophosphamide, should be minimised and
consideration given to the use of less oncogenic therapy,
such as methotrexate and mTOR inhibitors, such as
sirolimus [67]. There is evidence that mTOR inhibitors
have a beneficial effect in terms of cancer regression in
patients with post-transplant malignancy, and this will
need to be confirmed in long-term studies.
Conclusion
The benefits of treatment of IED with IS drugs must be
weighed against possible complications associated with
such therapy [41]. The vision-saving benefits of the
use of antimetabolites, calcineurin inhibitors and
biologicals are thought to outweigh the risks [27]. A
well-designed, comprehensive, multi-centre long-term
follow-up study is required to evaluate the risk of
malignancy in patients with specific IED diseases
treated with defined systemic IS therapy. Such a
study could provide valuable information that wouldinfluence the evaluation, investigation, prevention
strategies, routine follow-up and screening of individ-
uals. For example, patients at increased risk of malig-
nancy, especially skin cancers, should receive advice
regarding UV exposure and have regular skin examin-
ation. Immunisation against human papilloma virus
could reduce the prevalence of cervical cancer. Simi-
larly, long-term surveillance of patients treated with
systemic IS therapy for IED should include regular
systemic examination looking specifically for evidence
of malignancy (skin, cervix, lymph nodes and blood).
Until it has been ascertained as to whether or not there
is an increased risk of malignancy associated with
systemic IS therapy in patients with severe IED, in-
creased vigilance is required to ensure that patients are
regularly reviewed, appropriately and systematically
examined, investigated and have long-term follow-up
to detect and treat malignancies as early as possible.
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